Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-α2 therapy

Clinical and Experimental Immunology

Volumn 104, Issue 3, 1996, Pages 384-387

  Antonelli, G ^a   Giannelli, G ^b   Currenti, M ^c   Simeoni, E ^c   Del Vecchio, S ^c   Maggi, E ^a   Pistello, M ^a   Roffi, L ^d   Pastore, G ^b   Chemello, L ^e   Dianzani, F ^c  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antibodies to interferon; Hepatitis C; Hepatitis C treatment; Interferon alpha; Interferons; Resistanc to interferon therapy

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; INTERFERON ANTIBODY; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL; SEROCONVERSION;

EID: 9044230923     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.43747.x     Document Type: Article

References (18)

1. Hoofnagle JH. Interferon therapy of viral hepatitis. In: Baron S. Coppenhauer DH, Dianyani F et al., eds. Interferon: principles and medical applications. Galveston: The University of Texas Medical Branch at Galveston, 1992:433-62.
2. Jacyne MR, Thomas HC. Treatment of hepatitis C. Med Virol Rev 1993; 3:201-7.
3. Von Wussow P, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H. Clinical significance of anti-interferon antibodies during interferon therapy. Lancet 1987; 2:635-6.
4. Steis RG, Smith JW, Urha WJ et al. Resistance to recombinant interferon alpha-2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 1988; 318:1409-13.
5. Porres JC, Carreno V, Ruiz M, Marron JA, Bartolom J. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. Hepatol 1989; 8:351-7.
6. Lok SF, Lai CL, Leung KY. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatol 1990; 12:1266-70.
7. Casato M, Lagana B, Antonelli G, Dianzani F, Bonomo L. Long-term results of interferon therapy in essential mixed cryoglobulinemia. Blood 1991; 78:3142-7.
8. Milella M, Antonelli G, Santantonio T et al. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver 1993; 13:146-50.
9. Antonelli G, Dianzani F. Antibodies to interferon alpha in patients. Arch Virol 1993; 8:271-7.
10. Bonetti P, Diodati G, Drago C et al. Interferon antibodies in patients with chronic hepatitis C virus infection treated with recombinant interferon alpha-2a. J Hepatol 1994; 20:416-20.
11. Antonelli G, Currenti M, Turriziani O, Dianzani F. Neutralizing antibodies to interferon alpha: frequency in patients treated with different interferon preparations. J Infect Dis 1991; 163:882-5.
12. Giannelli G, Antonelli G, Fera G et al. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C. Clin Exp Immunol 1994; 97:4-9.
13. Finter NB. Why are there so many subtypes of alpha interferon? J Interferon Res 1991; special issue; 185-94.
14. Von Wussow P, Hartman F, Freund M, Poliwoda H, Deicher H. Leukocyte derived interferon-alpha in patients with antibodies to recombinant IFN-alpha 2b. Lancet 1988; i:882-3.
15. Brand CM, Leadbeater L, Budiman K, Lechner K, Gisslinger H. Successful re-treatment of an anti-interferon resistant polycythaemia vera patient with lymphoblastoid interferon- alpha N1 and in vitro studies on the specificity of the antibodies. Brit J Haematol 1994; 86:216-8.
16. Roffi L, Colloredo Mels G, Antonelli G et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatol 1995; 3:645-9.
17. Rosenblum MG, Unger BW, Gutterman JU, Hersh EM, David GS, Frincke JM. Modification of human leukocyte pharmacology with a monoclonal antibody. Cancer Res 1985; 45:2421-5.
18. Roffi L, Colloredo-Mels G, Bellati G et al. Breakthrough in patients with HCV chronic hepatitis: role of genotypes. Gastroenterol 1995; 108:1157.